Literature DB >> 27925197

Factor Xa Signaling Contributes to the Pathogenesis of Inflammatory Diseases.

Safieh Ebrahimi1, Sara Rezaei1, Parvaneh Seiri1, Mikhail Ryzhikov2, Seyed Isaac Hashemy3, Seyed Mahdi Hassanian1,4,5.   

Abstract

The coagulation protease Factor Xa (FXa) triggers a variety of signaling pathways through activation of protease-activated receptors (PARs) and non-PAR receptors. FXa-mediated signaling is strongly implicated in the pathogenesis of several inflammatory diseases including fibrosis, cardiovascular diseases, and cancer. Thus, targeting of FXa can have great clinical significance in terms of the treatment of these disorders. This review summarizes the current knowledge about the mechanism of FXa signaling in cellular and animal systems under (patho) physiological conditions for a better understanding and hence a better management of FXa-induced disorders. J. Cell. Physiol. 232: 1966-1970, 2017.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27925197     DOI: 10.1002/jcp.25714

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  3 in total

1.  Rivaroxaban improves vascular response in LPS-induced acute inflammation in experimental models.

Authors:  Armond Daci; Lorenzo Da Dalt; Rame Alaj; Shpejtim Shurdhiqi; Burim Neziri; Rrahman Ferizi; Giuseppe Danilo Norata; Shaip Krasniqi
Journal:  PLoS One       Date:  2020-12-10       Impact factor: 3.240

Review 2.  Biomaterials as Haemostatic Agents in Cardiovascular Surgery: Review of Current Situation and Future Trends.

Authors:  Horațiu Moldovan; Iulian Antoniac; Daniela Gheorghiță; Maria Sabina Safta; Silvia Preda; Marian Broască; Elisabeta Badilă; Oana Fronea; Alexandru Scafa-Udrişte; Mihai Cacoveanu; Adrian Molnar; Victor Sebastian Costache; Ondin Zaharia
Journal:  Polymers (Basel)       Date:  2022-03-16       Impact factor: 4.329

Review 3.  Potential Therapeutic Roles for Direct Factor Xa Inhibitors in Coronavirus Infections.

Authors:  Rami A Al-Horani
Journal:  Am J Cardiovasc Drugs       Date:  2020-12       Impact factor: 3.283

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.